Richard T. Laube

Gnubiotics Sciences SA is a Swiss biotech company that focuses on developing microbiome targeted candidates for both animals and humans. The private company is based in Epalinges, Switzerland. The company has developed a proprietary ultra-high resolution sequencing approach called RevelaBiome™, which enables detection and quantitation of bacterial taxonomy up to the strain level. The company's pipeline of microbiome targeted solutions includes Gnubiome Fi, a line of functional ingredients, and Amobiome Forte, a supplement line designed for immunomodulation, microbiome modulation, and microbiome recovery post antibiotic use in companion animals. The company has also developed microbiome biomarkers that offer a view on microbiome health as well as predispositions, onset, and progression of microbiome correlated diseases. The company was founded by Richard T. Laube, Yemi Adesokan, Bernardo Horta e Costa, Jean-Philippe Kunz. Jean-Philippe Kunz has been the CEO since incorporation.

Gnubiotics Sciences SA is a Swiss biotech company that focuses on developing microbiome targeted candidates for both animals and humans. The private company is based in Epalinges, Switzerland. The company has developed a proprietary ultra-high resolution sequencing approach called RevelaBiome™, which enables detection and quantitation of bacterial taxonomy up to the strain level. The company's pipeline of microbiome targeted solutions includes Gnubiome Fi, a line of functional ingredients, and Amobiome Forte, a supplement line designed for immunomodulation, microbiome modulation, and microbiome recovery post antibiotic use in companion animals. The company has also developed microbiome biomarkers that offer a view on microbiome health as well as predispositions, onset, and progression of microbiome correlated diseases. The company was founded by Richard T. Laube, Yemi Adesokan, Bernardo Horta e Costa, Jean-Philippe Kunz. Jean-Philippe Kunz has been the CEO since incorporation.

Gnubiotics Sciences SA is a Swiss biotech company that focuses on developing microbiome targeted candidates for both animals and humans. The private company is based in Epalinges, Switzerland. The company has developed a proprietary ultra-high resolution sequencing approach called RevelaBiome™, which enables detection and quantitation of bacterial taxonomy up to the strain level. The company's pipeline of microbiome targeted solutions includes Gnubiome Fi, a line of functional ingredients, and Amobiome Forte, a supplement line designed for immunomodulation, microbiome modulation, and microbiome recovery post antibiotic use in companion animals. The company has also developed microbiome biomarkers that offer a view on microbiome health as well as predispositions, onset, and progression of microbiome correlated diseases. The company was founded by Richard T. Laube, Yemi Adesokan, Bernardo Horta e Costa, Jean-Philippe Kunz. Jean-Philippe Kunz has been the CEO since incorporation.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Simply Good Foods USA, Inc. manufactures and sells weight control nutrition products. The firm offers meal kits, bars, frozen food and meals, shakes, and treats. The company was founded by Robert C. Atkins in 1989 and is headquartered in Denver, CO.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland.